SEC Filings
Summit Therapeutics Lets One Holder Resell Up To 108.96 Million Shares After Preferred Conversion
A prospectus supplement covers common stock issuable from a single holder's Class A Convertible Preferred shares.
SMMT
Summit Therapeutics (SMMT) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
Summit Therapeutics Drops Going-Concern Warning After AstraZeneca's $2.0 Billion Investment
The cancer drug developer now says its cash lasts at least 12 months, but AstraZeneca's stake converts into 108,955,369 common shares.
SEC Filings
Summit's Adjusted Quarterly Loss Widens To $160.7 Million Ahead Of November 14 FDA Decision
The drug developer held $629.8 million at September 30, before a $2.0 billion AstraZeneca investment closed on October 5.
SEC Filings
Summit Therapeutics Says Failed Share Vote Could Make Preferred Stock Redeemable
A special-meeting proxy ties more authorized common shares to preferred redemption risk, going-concern language and dilution.